Less than 10% of the millions eligible for the so-called "King Kong of weight loss drugs" will be able to get ... also to test ways of delivering this new generation of weight loss medications." ...
The GLP-1 drugs are "truly causing a lot of disruption for the surgeons and for the programs, and for patients," Thomas Tsai, MD, a bariatric surgeon at Brigham and Women's Hospital in Boston, told ...
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...